Citius Pharmaceuticals, Inc.

During the quarter ended June 30, 2025, none of our directors or officers adopted or terminated any contract or written plan for the purchase or sale of our securities.

On August 7, 2025, the Board of Directors of the Company approved (i) an extension by one year to August 14, 2026 for warrants to purchase an aggregate of 156,863 shares of common stock with an exercise price of $28.75 per share and (ii) an extension by one year to September 27, 2026 for warrants to purchase an aggregate of 111,732 shares of common stock with an exercise price of $19.25 per share (collectively, the “Investor Warrants”). The Investor Warrants are held by Leonard Mazur, the Company’s Chief Executive Officer and Chairman of the Board of Directors, and Myron Holubiak, the Company’s Executive Vice President and member of the Board of Directors, and were originally issued in August 2018 in a private placement conducted simultaneously with a registered direct offering of shares of common stock (the “2018 Offering”) and in an underwritten offering conducted in September 2019 (the “2019 Offering”), respectively, each managed by H. C. Wainwright & Co., LLC (“Wainwright”). Mr. Mazur and Mr. Holubiak participated in the offerings on the same basis as all other investors. Additionally, 7,577 warrants with an exercise price of $39.8438 per share were issued to Wainwright in connection with the 2018 Offering (the “Placement Agent Warrants) and 7,774 warrants with an exercise price of $27.9719 per share were issued to Wainwright in connection with the 2019 Offering (the “Underwriter Warrants” and together with the Investor Warrants and the Placement Agent Warrants, the “Warrants”) were extended by one year to August 8, 2026 and September 27, 2026, respectively. The Placement Agent Warrants and the Underwriter Warrants are held by certain representatives of Wainwright or their assignees. The terms of the Warrants were previously extended in August 2023 and August 2024 and September 2024, respectively. There are no other Warrants remaining outstanding from the 2018 Offering or the 2019 Offering and if such Warrants are fully exercised, the Company would receive approximately $7.2 million in cash proceeds.